Therapeutic Delivery of Pip4k2c‐Modified mRNA Attenuates Cardiac Hypertrophy and Fibrosis in the Failing Heart

Therapeutic Delivery of Pip4k2c‐Modified mRNA Attenuates Cardiac Hypertrophy and Fibrosis in the Failing Heart

Abstract Heart failure (HF) remains a major cause of morbidity and mortality worldwide. One of the risk factors for HF is cardiac hypertrophy (CH), which is frequently accompanied by cardiac fibrosis (CF). CH and CF are controlled by master regulators mTORC1 and TGF‐β, respectively. Type‐2‐phosphati...

Full description

Bibliographic Details
Main Authors: Ajit Magadum, Neha Singh, Ann Anu Kurian, Mohammad Tofael Kabir Sharkar, Nishat Sultana, Elena Chepurko, Keerat Kaur, Magdalena M. Żak, Yoav Hadas, Djamel Lebeche, Susmita Sahoo, Roger Hajjar, Lior Zangi
Format: Article
Language:English
Published: Wiley 2021-05-01
Series:Advanced Science
Subjects:
fibrosis
gene therapy
heart failure
hypertrophy
Online Access:https://doi.org/10.1002/advs.202004661

Internet

https://doi.org/10.1002/advs.202004661

Similar Items